Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis.

Chen S, Song X, Chen Z, Li X, Li M, Liu H, Li J.

PLoS One. 2013;8(2):e56380. doi: 10.1371/journal.pone.0056380. Epub 2013 Feb 11. Review.

2.

Prognostic role of CD133 expression in colorectal cancer: a meta-analysis.

Wang K, Xu J, Zhang J, Huang J.

BMC Cancer. 2012 Dec 5;12:573. doi: 10.1186/1471-2407-12-573.

3.

Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.

Kim ST, Sohn I, DO IG, Jang J, Kim SH, Jung IH, Park JO, Park YS, Talasaz A, Lee J, Kim HC.

Cancer Genomics Proteomics. 2014 Sep-Oct;11(5):259-66.

PMID:
25331798
4.

Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.

Reggiani Bonetti L, Migaldi M, Caredda E, Boninsegna A, Ponz De Leon M, Di Gregorio C, Barresi V, Scannone D, Danese S, Cittadini A, Sgambato A.

Scand J Gastroenterol. 2012 Oct;47(10):1211-7. Epub 2012 Aug 3.

PMID:
22856425
5.

Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review.

Qu H, Li R, Liu Z, Zhang J, Luo R.

Int J Clin Exp Pathol. 2013 Oct 15;6(11):2644-50. eCollection 2013. Review.

6.

Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study.

Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A.

Cancer Sci. 2008 Aug;99(8):1578-83. doi: 10.1111/j.1349-7006.2008.00849.x.

7.

Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.

Wu B, Sun C, Feng F, Ge M, Xia L.

J Exp Clin Cancer Res. 2015 May 14;34:44. doi: 10.1186/s13046-015-0163-4. Review.

8.

CD133 Expression in Lymph Node Metastases Is Associated with Tumor Aggressiveness During Lymph Node Metastasis in Colorectal Cancer.

Kazama S, Kishikawa J, Yasuda K, Otani K, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Kawai K, Hata K, Nozawa H, Yamaguchi H, Ishihara S, Sunami E, Watanabe T.

Anticancer Res. 2015 Dec;35(12):6599-605.

PMID:
26637875
9.

CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: a systematic review and meta-analysis.

Yiming L, Yunshan G, Bo M, Yu Z, Tao W, Gengfang L, Dexian F, Shiqian C, Jianli J, Juan T, Zhinan C.

Oncotarget. 2015 Dec 8;6(39):42019-27. doi: 10.18632/oncotarget.5714. Review.

10.

Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis.

Zhong C, Wu JD, Fang MM, Pu LY.

Tumour Biol. 2015 Sep;36(10):7623-30. doi: 10.1007/s13277-015-3487-y. Epub 2015 Apr 29.

PMID:
25921286
11.

Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients.

Takahashi S, Kamiyama T, Tomaru U, Ishizu A, Shida T, Osaka M, Sato Y, Saji Y, Ozaki M, Todo S.

Oncol Rep. 2010 Nov;24(5):1201-12.

PMID:
20878111
12.

Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review.

Wen L, Chen XZ, Yang K, Chen ZX, Zhang B, Chen JP, Zhou ZG, Mo XM, Hu JK.

PLoS One. 2013;8(3):e59154. doi: 10.1371/journal.pone.0059154. Epub 2013 Mar 22. Review. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/80c50c32-16b8-4099-98e4-af72154192b3.

13.

Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.

Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasako M, Mori M.

J Clin Oncol. 2011 Apr 20;29(12):1547-55. doi: 10.1200/JCO.2010.30.5151. Epub 2011 Mar 21.

PMID:
21422427
14.

CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy.

Mia-Jan K, Jung SY, Kim IY, Oh SS, Choi E, Chang SJ, Kang TY, Cho MY.

BMC Cancer. 2013 Mar 28;13:166. doi: 10.1186/1471-2407-13-166.

15.

Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.

Jing F, Kim HJ, Kim CH, Kim YJ, Lee JH, Kim HR.

Int J Oncol. 2015 Apr;46(4):1582-8. doi: 10.3892/ijo.2015.2844. Epub 2015 Jan 23.

PMID:
25625240
16.

Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients.

Shimada R, Iinuma H, Akahane T, Horiuchi A, Watanabe T.

Oncol Rep. 2012 Apr;27(4):947-53. doi: 10.3892/or.2012.1649. Epub 2012 Jan 19.

17.

Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis.

Yang K, Chen XZ, Zhang B, Yang C, Chen HN, Chen ZX, Zhou ZG, Chen JP, Hu JK.

Int J Biol Markers. 2011 Jul-Sep;26(3):173-80. doi: 10.5301/JBM.2011.8551. Epub 2011 Jul 22.

PMID:
21786247
18.

Overexpression of B7-H3 in CD133+ colorectal cancer cells is associated with cancer progression and survival in human patients.

Bin Z, Guangbo Z, Yan G, Huan Z, Desheng L, Xueguang Z.

J Surg Res. 2014 May 15;188(2):396-403. doi: 10.1016/j.jss.2014.01.014. Epub 2014 Jan 24.

PMID:
24630518
19.

Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer.

Kemper K, Versloot M, Cameron K, Colak S, de Sousa e Melo F, de Jong JH, Bleackley J, Vermeulen L, Versteeg R, Koster J, Medema JP.

Clin Cancer Res. 2012 Jun 1;18(11):3132-41. doi: 10.1158/1078-0432.CCR-11-3066. Epub 2012 Apr 10.

20.

A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors.

Ernst A, Aigner M, Nakata S, Engel F, Schlotter M, Kloor M, Brand K, Schmitt S, Steinert G, Rahbari N, Koch M, Radlwimmer B, Weitz J, Lichter P.

Pathology. 2011 Apr;43(3):220-7. doi: 10.1097/PAT.0b013e328344e391.

PMID:
21436631

Supplemental Content

Support Center